pharma · Asthma · Type 2 Diabetes
AstraZeneca
AstraZeneca is a pharma organization headquartered in Södertälje, SE. Primary therapeutic focus areas include Asthma, Type 2 Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease,
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 129
- Drugs
- 77
- Patents
- 25
Tezepelumab
Phase 3 · mab · Chronic Obstructive Pulmonary Disease (COPD)
Tezepelumab for Chronic Obstructive Pulmonary Disease (COPD) is a Phase 3 program (mab) at AstraZeneca with 2 ClinicalTrials.gov record(s).
Internal code D5241C00006
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AstraZeneca
- Phase
- Phase 3
- Modality
- mab
- Indication
- Chronic Obstructive Pulmonary Disease (COPD)
- Status
- active
- Trials
- 2